United Therapeutics Corporation (UTHR) Stock Analysis

United Therapeutics Corporation (UTHR) is a publicly traded company in the HEALTHCARE sector. It trades at $544.62, carries a market capitalization of $23.12B, a price-to-earnings ratio of 20.13. This page summarizes the public market data, fundamentals, and frequently asked questions for UTHR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

United Therapeutics Corporation currently has a Neutral sentiment score of 0.10.

About United Therapeutics Corporation

United Therapeutics Corporation (UTHR) is a pioneering biotechnology company dedicated to developing and commercializing groundbreaking therapies for patients suffering from chronic and life-threatening conditions, particularly targeting pulmonary hypertension and organ transplantation. Based in Silver Spring, Maryland, the company boasts a strong pipeline and innovative technologies that address critical unmet medical needs in the U.S. and worldwide. With a steadfast commitment to advancing ...

GNG Research Analysis

GNG Research scores United Therapeutics Corporation (UTHR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for UTHR.

Frequently Asked Questions

Does UTHR pay dividends?

United Therapeutics Corporation (UTHR) does not currently pay a regular dividend.

What is UTHR's P/E ratio?

United Therapeutics Corporation has a price-to-earnings (P/E) ratio of 20.13.

What is UTHR's market cap?

United Therapeutics Corporation (UTHR) has a market capitalization of $23.12B with a current stock price of $544.62.